MedTrace Logo

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

NCT05616923 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-05-30

No results posted yet for this study

Summary

This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea

Conditions

  • Rosacea, Erythematotelangiectatic

Interventions

DRUG

Trametinib

Topical cream containing 0.1 mg/g trametinib

Sponsors & Collaborators

  • Albany Research Institute, Inc.

    lead OTHER

Principal Investigators

  • Jacqueline Busingye, MD · Stratton VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05616923 on ClinicalTrials.gov